

Published in final edited form as:

Org Lett. 2008 October 16; 10(20): 4605–4608. doi:10.1021/ol801868a.


Synthesis of 3,5-Difluorotyrosine-Containing Peptides:

Application in Substrate Profiling of Protein Tyrosine Phosphatases

Bhaskar Gopishetty, Lige Ren, Tiffany M. Waller, Anne-Sophie Wavreille, Miguel Lopez, Amit Thakkar, Jinge Zhu, and Dehua Pei

Department of Chemistry and Ohio State Biochemistry Program, The Ohio State University, 100 West 18th Avenue, Columbus, Ohio 43210

Abstract



Fully protected 3,5-difluorotyrosine (F₂Y), Fmoc-F₂Y(tBu)-OH, is efficiently prepared by a chemo-enzymatic process and incorporated into individual peptides and combinatorial peptide libraries. The F₂Y-containing peptides display similar kinetic properties toward protein tyrosine phosphatases (PTPs) to their corresponding tyrosine-containing counterparts, but are resistant to tyrosinase action. These properties make F₂Y a useful tyrosine surrogate during peptide library screening for optimal PTP substrates.

Replacement of a hydrogen with fluorine results in a small increase in the molecular size but often dramatically different physical, chemical, and biological properties of the molecule.¹ As such, fluorinated compounds provide useful mechanistic probes of enzyme-catalyzed reactions and other biological processes. For example, ring fluorinated analogs of tyrosine have been used to examine the catalytic mechanisms of tyrosinase,² tyrosine phenolase,³ protein tyrosine kinase and phosphatase,^{4,5} Δ5-3-ketosteroid isomerase,⁶ and ribonucleotide reductase.⁷

Our own interest in fluorotyrosines stems from our ongoing studies on protein tyrosine phosphatases (PTPs), a large family of enzymes that catalyze the hydrolysis of phosphotyrosine (pY) in proteins back to tyrosine and inorganic phosphate. A major challenge in the PTP field is to determine the physiological substrates and cellular function of these enzymes. We recently developed a combinatorial library method to profile the substrate specificity of PTPs and subsequently used the specificity information to predict the protein substrates of the PTPs.⁸ A key element of the technique involved selective derivatization of the reaction product (i.e., tyrosine) with a chemical tag (e.g., biotin). This was accomplished by first oxidizing the tyrosine side chain into an orthoquinone with O₂ and tyrosinase, followed by conjugate addition

with biotin-hydrazide. To prevent false positives from unreacted substrates, tyrosine was excluded from the library. However, PTPs may require tyrosine residues for optimal binding and catalysis. Thus, we envisaged the inclusion of a fluorinated tyrosine into the peptide library as a tyrosinase-resistant tyrosine surrogate. Among all of the known mono-, di-, and multiply fluorinated tyrosine analogs, we reasoned that 3,5-difluorotyrosine (F₂Y, compound **1** in Scheme 1) should contain the minimal number of fluorine substitution to render it resistant to tyrosinase action. Because F and H atoms have similar van der Waals radii (1.35 Å for F and 1.10 Å for H), Tyr and F₂Y are essentially isosteric, although the side chain of F₂Y has a lower pK_a value (7.2) than that of Tyr (9.9).⁹

F₂Y has previously been synthesized both chemically¹⁰ and enzymatically.^{3,4,7} Synthesis of F₂Y-containing peptides employed side chain unprotected Fmoc-F₂Y-OH and the resulting peptides were purified by HPLC.^{4,7} The reported peptides were either very short or contained F₂Y near their N-termini (therefore no repeated coupling reactions after incorporation of F₂Y) and each contained only a single F₂Y residue. We felt that the unprotected F₂Y side chain might be problematic with peptide library synthesis, during which more forcing coupling conditions are typically employed to drive reactions to completion, some library members will contain multiple F₂Y residues, and HPLC purification is not an option. In this report, we describe the synthesis of fully protected F₂Y, its incorporation into peptides and peptide libraries, and its activity against PTPs in comparison with the tyrosine counterparts.

We employed the enzymatic synthesis originally developed by Phillips and coworkers³ to prepare multigram quantities of F₂Y from 2,6-difluorophenol, pyruvate, and NH₃ (Scheme 1). Treatment of F₂Y with N-(9-fluorenylmethylcarbonyloxy)succinimide in 10% sodium carbonate gave N^α-Fmoc-F₂Y-OH, which was subsequently converted into its methyl ester **2** using thionyl chloride in refluxing methanol. The phenol group was next protected as a tert-butyl ether by treatment with isobutylene and H₂SO₄. Finally, hydrolysis of the methyl ester by LiOH in THF/H₂O gave the desired N^α-Fmoc-F₂Y(tBu)-OH (**3**) in 24% overall yield (from F₂Y).

Three F₂Y-containing peptides and their corresponding Tyr-containing counterparts were synthesized on the solid phase by using standard Fmoc/HBTU chemistry (Table 1, compounds **4-9**). Peptide **5** is derived from a known pY motif of receptor protein tyrosine kinase erbB2,¹¹ whereas peptides **7** and **9** are analogous to the preferred substrates of PTP1B (the prototypical PTP), previously identified from a peptide library.⁸ These peptides contain F₂Y (or Tyr) at pY-3, pY-2, or pY-1 position (relative to pY, which is designated as position 0). Earlier studies have shown that residues at the N-terminal side of pY are most critical in defining the substrate specificity of PTPs.¹² During peptide synthesis, N^α-Fmoc-F₂Y(tBu)-OH was efficiently incorporated into peptides without incidence (as judged by ninhydrin tests), despite that it was used at only 1.5 equivalents (four equivalents were used for all other amino acids). Reversed-phase HPLC analysis of the crude peptides showed that in each case, the desired peptide was the major product (see Figure 1, for example). Peptides **4-9** were purified by preparative HPLC and their kinetic activities toward PTP1B (i.e., *k*_{cat}, *K*_M, and *k*_{cat}/*K*_M values) were determined at pH 7.4 (Table 1). The data show that substitution of F₂Y for tyrosine resulted in minimal changes in kinetic constants (≤2-fold, which is within the margin of experimental error). Thus, F₂Y is a good functional mimic of tyrosine, in terms of binding to the active site of PTPs.

Next, a pair of Tyr- and F₂Y-containing peptides (peptides **8** and **9** in Table 1) were tested for activity against tyrosinase. The peptides were individually treated with tyrosinase in the presence of atmospheric O₂ and excess biotin hydrazide. Reversed-phase HPLC/MS analysis of the reaction mixtures revealed that the Tyr-containing peptide REYEFpYAA was quantitatively converted into a new species, which had an increased retention time (from 32.0

to 34.5 min) and molecular mass (from m/z 1168.4. to 1440.7) (Figure S1 in Supporting Information). The increase of 272.3 amu in molecular mass is consistent with the addition of a single biotin hydrazide molecule to the tyrosine side chain. As expected, the F₂Y-containing peptide (**8**) was completely resistant to tyrosinase action.

Finally, to test whether F₂Y is compatible with peptide library synthesis, screening, and post-screening sequence identification, we designed a pY peptide library containing five random positions immediately N-terminal to pY [SAXXXXXpYAABBRM-resin, where B is β -alanine and X is F₂Y, norleucine (Nle), or any of the 17 proteinogenic amino acids excluding Met, Cys and Tyr]. The library was synthesized on polyethylene glycol polyacrylamide (PEGA) resin¹³ by the split-and-pool method.¹⁴ A portion of the resulting one-bead-one-compound (OBOC) library (~40,000 beads) was treated with 1.0 nM PTP1B for 20 min (at pH 7.4), followed by incubation with 1.2 μ M mushroom tyrosinase in the presence of atmospheric O₂ and 6 mM 3-methyl-2-benzothiazolinonehydrazine (MBTH). Under these conditions, only beads that carried the most preferred substrates of PTP1B were dephosphorylated (usually only partially). The exposed tyrosine side chain was subsequently oxidized by the excess tyrosinase activity into an orthoquinone, which was trapped by reaction with MBTH to form a dark pink pigment (Figure 2a).¹⁵ Thus, as a result of this reaction cascade, a bead carrying a preferred PTP1B substrate would turn pink/red, whereas beads carrying poor substrates would not. This was indeed the case (Figure 2b). The pink/red colored beads were removed from the library and individually sequenced by partial Edman degradation/mass spectrometry¹⁶ to reveal the most preferred PTP1B substrates (Table 2). Figure 2c shows an example of the MS spectrum derived from one of the pink beads (bead No. 2 in Table 2), carrying the sequence of SAVITDF₂YpYAABBRM. Our results are in agreement with earlier reports that PTP1B prefers acidic residues at the N-terminal side of pY, especially at the pY-2 position.^{8,12,17} A control experiment without the PTP1B treatment resulted in no pink/red colored beads at all (data not shown). Since ~25% of the library members contain at least one F₂Y residue in the random region, the lack of any pink/red beads in the control provides further evidence that F₂Y is completely resistant to tyrosinase action. Most importantly, F₂Y is compatible with every aspect of library synthesis, screening, and sequence identification.

In summary, we have found that F₂Y is a functional, tyrosinase-resistant mimetic of tyrosine for applications such as defining the substrate specificity of PTPs through combinatorial library screening. An efficient method has been developed for the chemoenzymatic synthesis of fully protected F₂Y and its incorporation into peptides and peptide libraries. In addition, an improved PTP screening assay has been developed by employing MBTH as the coupling reagent. Because the pink/red pigment is only formed on the beads that have undergone PTP reaction, the current method does not generate any false positives and is operationally straightforward. Application of the methodologies to systematically profile the substrate specificity of PTPs is currently ongoing in our laboratory and will be reported elsewhere in due course.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgment

This work was supported by National Institutes of Health (GM062820).

References

- (1). Hagmann WK. *J. Med. Chem* 2008;51:4359–4369. [PubMed: 18570365]

- (2). Battaini G, Monzani E, Casella L, Lonardi E, Tepper AWJW, Canters GW, Bubacco L. *J. Biol. Chem* 2002;277:44606–44612. [PubMed: 12235154]
- (3). Phillips RS, Von Tersch RL, Secundo F. *Eur. J. Biochem* 1997;244:658–663. [PubMed: 9119037]
- (4). Kim K, Cole PA. *J. Am. Chem. Soc* 1998;120:6851–6858.
- (5). Martin B, Pallen CJ, Wang JH, Graves DJ. *J. Biol. Chem* 1985;260:14932–14937.
- (6). Brooks B, Philips RS, Benisek WF. *Biochemistry* 1998;37:9738–9742. [PubMed: 9657686]
- (7). Yee CS, Chang MCY, Ge J, Nocera DG, Stubbe J. *J. Am. Chem. Soc* 2003;125:10506–10507. [PubMed: 12940718]
- (8). Garaud M, Pei D. *J. Am. Chem. Soc* 2007;129:5366–5367. [PubMed: 17417856]
- (9). Seyedsayamdost MR, Reece SY, Nocera DG, Stubbe J. *J. Am. Chem. Soc* 2006;128:1569–1579. [PubMed: 16448128]
- (10). Kirk KL. *J. Org. Chem* 1980;45:2015–2016.
- (11). Yamamoto T, Ikawa S, Akiyama T, Nomura N, Miyajima N, Saito T, Toyoshima K. *Nature* 1986;319:230–234. [PubMed: 3003577]
- (12). (a) Zhang Z-Y, Thieme-Sefler AM, Maclean D, McNamara DJ, Dobrusin EM, Sawyer TM, Dixon JE. *Proc. Natl. Acad. Sci. U. S. A* 1993;90:4446–4450. [PubMed: 7685104] (b) Zhang Z-Y, Maclean D, McNamara DJ, Sawyer TK, Dixon JE. *Biochemistry* 1994;33:2285–2290. [PubMed: 7509638]
- (13). Meldal M. *Tetrahedron Lett* 1992;33:3077–3080.
- (14). (a) Lam KS, Salmon SE, Hersh EM, Hruby VJ, Kazmierski WM, Knapp RJ. *Nature* 1991;354:82–84. [PubMed: 1944576] (b) Houghten RA, Pinilla C, Blondelle SE, Appel JR, Dooley CT, Cuervo JH. *Nature* 1991;354:84–86. [PubMed: 1719428] (c) Furka A, Sebastyen F, Asgedom M, Dibo G. *Int. J. Peptide Protein Res* 1991;37:487–493. [PubMed: 1917305]
- (15). Winder AJ, Harris H. *Eur. J. Biochem* 1991;198:317–326. [PubMed: 1674912]
- (16). Thakkar A, Wavreille A-S, Pei D. *Anal. Chem* 2006;78:5935–5939. [PubMed: 16906744]
- (17). (a) Pellegrini MC, Liang H, Mandiyan S, Wang K, Yuryev A, Vlattas I, Sytwu T, Li Y-C, Wennogle LP. *Biochemistry* 1998;37:15598–15606. [PubMed: 9843364] (b) Vetter SW, Keng Y-F, Lawrence DS, Zhang Z-Y. *J. Biol. Chem* 2000;275:2265–2268. [PubMed: 10644673] (c) Walchli S, Espanel X, Harrenga A, Rossi M, Cesareni G, van Huijsduinen RH. *J. Biol. Chem* 2004;279:311–318. [PubMed: 14578355]






Figure 1.
HPLC analysis of peptide **4** on a C-18 column, eluted with a linear gradient of 10-60% CH₃CN in H₂O containing 0.1% trifluoroacetic acid over 50 min.

**Figure 2.**

a) Reactions involved in library screening against PTP and bead coloration; b) A portion of the OBOC pY library after treatment with PTP1B (1.0 nM) and tyrosinase (1.2 μ M) (viewed under a dissecting microscope); c) MALDI-TOF spectrum of peptide SAVITDF₂YpYAABBRM* and its truncation products after partial Edman degradation (derived from a single PEGA resin bead). M*, homoserine lactone.



Scheme 1.
Synthesis of Fully Protected F_2Y

Table 1Comparison of the Kinetic Constants of F₂Y- and Tyr-Containing Peptides against PTP1B (pH 7.4)

peptide	k_{cat} (s ⁻¹)	K_{M} (μM)	$k_{\text{cat}}/K_{\text{M}}$ (μM ⁻¹ s ⁻¹)
DNLF _{2Yp} YWD-NH ₂ (4)	36 ± 1	3.6 ± 0.4	10.0
DNLY _p YWD-NH ₂ (5)	32 ± 1	5.8 ± 0.8	5.5
DDTF _{2Y} DpYAA-NH ₂ (6)	36 ± 2	13 ± 3	2.7
DDTYDpYAA-NH ₂ (7)	33 ± 1	14 ± 2	2.3
REF _{2Y} EFpYAA-NH ₂ (8)	44 ± 2	14 ± 2	3.2
REYEFpYAA-NH ₂ (9)	33 ± 1	6.0 ± 0.7	5.4

Table 2

A Partial List of the Selected PTP1B Substrates

Bead No.	Peptide sequence
1	QDVDA _p YAA
2	VITDF _{2Yp} YAA
3	LQF _{2Y} DN _p YAA
4	ITMDQ _p YAA
5	WGTDS _p YAA
6	SSFDV _p YAA
7	SRHEW _p YAA
8	ETDFA _p YAA
9	NDLF _{2Y} E _p YAA
10	FTSGL _p YAA

M, norleucine.